
Implantica receives FDA approval for RefluxStop® – Opening the U.S. market
VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the company’s implant-based treatment for gastroesophageal reflux disease (GERD). The approval allows Implantica to begin commercial launch activities in the United States, the world’s largest medical device market.








